Peptide finder

What are you trying to change?

Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive. So you can see where the evidence is before you choose.

1. 01RapastinelPeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 5 completed trials, 2,614 people given it.

   1,087 people3 studies

   • A second large trial, two doses instead of one, and the same answer. Six hundred and fifty eight adults with depression got rapastinel at a lower or a higher weekly dose, or a dummy drip. After three weeks all three groups had improved by about the same amount. Neither dose pulled away from the dummy. The company...

     ClinicalTrials.gov, Naurex / Allergan, 2016 · 658 people

   • A third large trial, and a third failure. Four hundred and twenty nine adults with depression got a weekly drip of rapastinel or a dummy. Depression scores fell a little further on the drug after three weeks. The gap was small enough that chance alone routinely produces gaps that size. The company posted the figures...

     ClinicalTrials.gov, Naurex / Allergan, 2016 · 429 people

   • Tested properly in a large trial, and it did not work. Four hundred and sixty five adults with depression got a weekly drip of rapastinel or a dummy on top of their usual antidepressant. After three weeks, depression scores had fallen by the same amount in both groups. If anything the dummy group did slightly better....

     ClinicalTrials.gov, Naurex / Allergan, 2016 · number of people not given

2. 02HydralazineSmall moleculeStrong. At least two finished studies in people, and at least 1,000 people who took it. 3 completed trials, 1,724 people given it.4 reported

   1,050 people1 study

   • In 1,050 Black patients with advanced heart failure, a fixed-dose pill of hydralazine and a nitrate, on top of modern treatment, cut deaths so clearly the trial was stopped early. 6.2% died on the pill against 10.2% on a dummy pill. Again a two-drug pill, in one specific group of people.

     The New England Journal of Medicine, 2004 · 1,050 people

3. 03DHEAHormoneModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 267 people given it.5 reported

   168 people2 studies1 found nothing

   • found nothingThe biggest study of DHEA against a dummy pill as an anti-ageing supplement found nothing that mattered. 144 older men and women with low levels took it for two years. The hormone went up and little else changed. Body shape, strength, fitness, blood sugar control and quality of life did not get better. Bone density...

     The New England Journal of Medicine, 2006 · 144 people

   • In women whose adrenal glands make no DHEA, replacing it helped mood and sexual interest. 24 women took DHEA for four months and a dummy pill for four months. It is a study of people who lack the hormone, not of ageing.

     The New England Journal of Medicine, 1999 · 24 people

4. 04Melanotan IPeptideModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 170 people given it.8 reported

   432 people3 studies1 found nothing

   • A safety study required by European regulators, and the company that sells the drug is all over it. 200 patients were treated and nobody was left untreated, so there is no comparison group. Quality of life scores rose against where patients started, and about nine in ten who began treatment were still on it. Several...

     Photodermatology, Photoimmunology and Photomedicine, 2025 · 200 people

   • found nothingRegulators ordered this follow-up study, and it found real gains in daily life. 117 patients at one hospital were tracked for about two years. On average they gained roughly six more hours outside each week, and their quality of life scores rose. Painful sun reactions still happened as often and lasted as long; they...

     JAMA Dermatology, 2020 · 117 people

   • People with a painful light-intolerance disease felt far better on afamelanotide, but nobody got a dummy implant. 115 patients received just over a thousand implants across up to eight years at clinics in Rome and Zurich. Their quality of life scores started at about a third of the best possible and rose to roughly...

     British Journal of Dermatology, 2015 · 115 people

5. 05Semax / SelankBlendModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 172 people given it.9 reported

   62 people1 study

   • Selank calmed anxiety about as well as a standard sedative did. Sixty two people with long running anxiety or exhaustion were split by chance between Selank and medazepam, a drug in the same family as valium. Both groups improved by a similar amount, and the Selank group was also described as less tired and more...

     Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008 · 62 people

6. 06Semax with selank and dihexaBlendLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 62 people given it.7 reported

   62 people1 study

   • Selank calmed anxiety about as well as an older anti-anxiety drug, in a small Russian study. 62 patients with long-running anxiety or nervous exhaustion were treated, 30 with selank and 32 with medazepam. They were rated on standard anxiety scales. The two drugs came out about the same, and selank also lifted energy...

     Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008 · 62 people

7. 07DSIP with selank and epitalonBlendLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 62 people given it.6 reported

   62 people1 study

   • Selank eased anxiety about as well as an older anti-anxiety drug, in a small Russian study. 62 patients were treated, 30 on selank and 32 on medazepam, with similar results on standard anxiety scales. One detail matters in a product sold for sleep. Selank also acted as a mild stimulant in that study, lifting energy...

     Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008 · 62 people

8. 08InulinSupplementLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 39 people given it.6 reported

   39 people1 study

   • Inulin made constipation better, in a small test that ran into a design problem. 39 adults with long-running constipation took 12 g of chicory inulin daily for four weeks and a dummy for four more. Each person tried both in turn without knowing which. Bowel frequency, belly symptoms and quality of life all improved on...

     BMC Gastroenterology, 2025 · 39 people

9. 09SemaxPeptideModerate. At least one finished study in people, and at least 100 people who took it. 4 completed trials, 354 people given it.9 reported

   27 people1 study

   • Semax was measured against a nerve test and it did nothing. Twenty seven people with motor neuron disease took semax up the nose for two ten day courses. Their nerve and muscle testing did not change, and neither did the clinical ratings of their disease. The only score that moved was how they rated their own quality...

     Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2007 · 27 people

10. 10MelittinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 5 completed trials, 658 people given it.4 reported

    26 people1 study

    • Bee sting therapy failed on every measure it was tested on. Twenty six people with relapsing multiple sclerosis were stung up to twenty times a session, three times a week, for six months. Brain scans showed no fewer new lesions. Relapses, disability, fatigue and quality of life were all unchanged. Nobody was...

      Neurology, 2005 · 26 people

11. 11Neuropeptide YPeptideLimited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, 20 people given it.5 reported

    20 people1 study1 found nothing

    • found nothingThe only time neuropeptide Y itself has been given to people was a first safety look, not an answer. Twenty six people with PTSD sprayed either the peptide or a dummy up the nose, then swapped a week later, and nobody involved knew the order. Twenty four finished both days. Even the highest dose caused no trouble. One...

      International Journal of Neuropsychopharmacology, 2018 · 20 people

12. 12SermorelinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 139 people given it.8 reported

    19 people1 study1 found nothing

    • found nothingThe hormone response faded while the injections carried on. Nineteen adults aged 55 to 71 injected salt water nightly for a month, then a sermorelin-like peptide for four more months. Growth hormone and its main blood marker rose within two weeks, stayed up for three months, then drifted back to where they started...

      Journal of Clinical Endocrinology and Metabolism, 1997 · 19 people

13. 13ARA-290PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 5 completed trials, 95 people given it.7 reported

    9 people1 study

    • Every objective measure in this small trial stayed flat. Nine people with swelling at the centre of the retina injected cibinetide daily for three months, and eight finished. Their vision did not improve. Neither did retinal thickness, retinal sensitivity or tear production. The only thing that rose was how they rated...

      Journal of Clinical Medicine, 2020 · 9 people

14. 14DSIPPeptideLimited. People have taken it in a published study, but fewer than 100 of them. 6 completed trials, 7 people given it.8 reported

    number of people not given1 study

    • Withdrawal signs eased, and the study cannot prove the drug did it. 107 hospital patients in Geneva coming off alcohol or opioids got vein injections up to six times a day. Most of those assessed had a clear drop in visible signs: racing heart, tremor, sweating and watering eyes. Within one to three days of stopping,...

      European Neurology, 1984 · number of people not given

15. 15NemifitidePeptideModerate. At least one finished study in people, and at least 100 people who took it. 5 completed trials, 177 people given it.

    number of people not given1 study

    • The result here depends on when you look and who you count. Eighty one adults with depression got a shot of nemifitide at one of two strengths, or a dummy, on weekdays for two weeks. The higher dose beat the dummy at one chosen moment, a week after the shots had stopped. It separated from the dummy only among the more...

      International Journal of Neuropsychopharmacology, 2006 · number of people not given

16. 16NicotinamideSupplementModerate. At least one finished study in people, and at least 100 people who took it. 4 completed trials, 591 people given it.2 reported

    number of people not given1 study1 found nothing

    • found nothingThe same team tried to repeat the skin cancer result in transplant patients and it did not work. 158 organ transplant recipients who already had repeated skin cancers took the same dose for a year. New cancers came up 207 times on the vitamin and 210 times on the dummy pill, which is no difference at all. Nothing...

      New England Journal of Medicine, 2023 · number of people not given

17. 17Kisspeptin-54PeptideModerate. At least one finished study in people, and at least 100 people who took it. 5 completed trials, 122 people given it.8 reported

    number of people not given1 study1 found nothing

    • found nothingKisspeptin did not touch anxiety. People were given either kisspeptin or a dummy, and their reproductive hormones rose just as expected. Their anxiety did not change at all. This is about the only study in the whole kisspeptin field that measured something psychological rather than a hormone level, and the answer it...

      The Journal of Clinical Endocrinology and Metabolism, 2025 · number of people not given

18. 18PT-141 with oxytocinBlendLimited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, 10 people given it.6 reported

    number of people not given1 study

    • Oxytocin was tested properly for sex problems in women, and it did not beat a dummy spray. Thirty women used an oxytocin nasal spray or a dummy spray before sex. Each tried both over 22 weeks, and nobody knew which was which. Sexual function scores rose 26% on oxytocin and 31% on the dummy. Distress about sex fell 36%...

      Fertility and Sterility, 2015 · number of people not given

19. 19ErythropoietinBiologicStrong. At least two finished studies in people, and at least 1,000 people who took it. 3 completed trials, 4,641 people given it.6 reported

    number of people not given1 study

    • Pushing blood counts up to normal in kidney disease harmed people. 1,432 adults with long-term kidney disease were treated towards either a high or a lower blood count target, for about 16 months. Deaths, heart attacks, heart failure hospital stays and strokes were more common in the high target group, 125 events...

      New England Journal of Medicine, 2006 · number of people not given

20. 20Kisspeptin-10PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 4 completed trials, 44 people given it.8 reported

    29 people1 study

    • Kisspeptin-54 changed how men's brains responded to sexual and romantic images, and lifted low mood slightly. Twenty-nine healthy men were scanned after receiving the peptide or a dummy. Emotional areas of the brain reacted more strongly to the images on the peptide. This is a brain scan signal and a mood...

      Journal of Clinical Investigation, 2017 · 29 people

21. 21TestosteroneHormoneModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 5,246 people given it.10 reported

    number of people not given1 study1 found nothing

    • found nothingTestosterone helped older men with sex and did much less for everything else. It raised their levels to what a man in his twenties or thirties would have. Sex drive, sexual activity and erections all clearly got better. Energy did not get better at all. Walking distance only improved when three studies were lumped...

      New England Journal of Medicine, 2016 · number of people not given

22. 22SelankPeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 192 people given it.8 reported

    number of people not given0 studies
23. 23HCGBiologicLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 55 people given it.8 reported

    number of people not given0 studies
24. 24Vitamin B12SupplementLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, none stating how many people.4 reported

    number of people not given0 studies

1. 01OveporextonSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 6 completed trials, 441 people given it.

   168 people2 studies

   • This is about as strong as evidence for a sleep drug gets. Two trials put people with narcolepsy type 1 on oveporexton pills or dummy pills for three months. Nobody involved knew which. People on the drug stayed awake far longer on a standard staying-awake test, while the dummy group drifted slightly the other way....

     New England Journal of Medicine, 2026 · 168 people

   • The earlier and smaller test pointed the same way. 112 people with narcolepsy type 1 were split by chance across four dose schedules or a dummy, for two months. People on the drug stayed awake much longer on the standard test, while the dummy group slipped slightly. Insomnia hit about half of them, and a third had a...

     New England Journal of Medicine, 2025 · number of people not given

2. 02SermorelinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 139 people given it.8 reported

   19 people1 study1 found nothing

   • found nothingThe hormone response faded while the injections carried on. Nineteen adults aged 55 to 71 injected salt water nightly for a month, then a sermorelin-like peptide for four more months. Growth hormone and its main blood marker rose within two weeks, stayed up for three months, then drifted back to where they started...

     Journal of Clinical Endocrinology and Metabolism, 1997 · 19 people

3. 03DSIPPeptideLimited. People have taken it in a published study, but fewer than 100 of them. 6 completed trials, 7 people given it.8 reported

   number of people not given2 studies

   • Sleep improved slightly, and the researchers said the improvement was not worth much. 16 people with long term sleeplessness were matched into pairs, and nobody knew who got DSIP and who got sugar water. Each had a vein injection before three of five nights in a sleep lab. Those on DSIP fell asleep faster and slept a...

     Neuropsychobiology, 1992 · number of people not given

   • Withdrawal signs eased, and the study cannot prove the drug did it. 107 hospital patients in Geneva coming off alcohol or opioids got vein injections up to six times a day. Most of those assessed had a clear drop in visible signs: racing heart, tremor, sweating and watering eyes. Within one to three days of stopping,...

     European Neurology, 1984 · number of people not given

4. 04TirzepatidePeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 9 completed trials, 22,802 people given it.11 reported

   number of people not given1 study

   • It worked for sleep apnea, and the change was big. Adults with obesity and moderate to severe sleep apnea took tirzepatide or a dummy injection for a year, across two trials. Breathing interruptions during sleep dropped by roughly 25 an hour more than on the dummy. That count is the measure doctors use to grade how...

     New England Journal of Medicine, 2024 · number of people not given

5. 05MK-677Small moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 65 people given it.11 reported

   number of people not given1 study

   • MK-677 deepened sleep in young adults. Young and older volunteers each took the drug and a dummy in turn, so every person acted as their own comparison. In the young group the deepest stage of sleep rose by about half, and dreaming sleep by more than a fifth. The figures reported are for the young subjects, not the...

     Neuroendocrinology, 1997 · number of people not given

6. 06GHRP-6PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 5 completed trials, 42 people given it.8 reported

   number of people not given1 study1 found nothing

   • found nothingThis is where the cortisol worry about GHRP-6 comes from, and it is a human measurement. Healthy men were given four small injections across one night, against a dummy on another. Growth hormone roughly tripled, and so did cortisol, with the stress hormone that drives it rising too. Light sleep gained about...

     Neuroendocrinology, 1995 · number of people not given

7. 07EpitalonPeptideModerate. At least one finished study in people, and at least 100 people who took it. 5 completed trials, 266 people given it.6 reported

   number of people not given0 studies
8. 08NMNSupplementLimited. People have taken it in a published study, but fewer than 100 of them. 4 completed trials, 94 people given it.6 reported

   number of people not given0 studies
9. 09SomatropinBiologicLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 84 people given it.9 reported

   number of people not given0 studies
10. 10HCGBiologicLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 55 people given it.8 reported

    number of people not given0 studies
11. 11Vitamin B12SupplementLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, none stating how many people.4 reported

    number of people not given0 studies
12. 12RapamycinSmall moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 25 people given it.8 reported

    number of people not given0 studies
13. 13EnclomipheneSmall moleculePreliminary. Studied in people, but no published study has had people take it. 1 human study where nobody was given it.6 reported

    number of people not given0 studies
14. 14TestosteroneHormoneModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 5,246 people given it.10 reported

    number of people not given0 studies
15. 15OxandroloneHormonePreliminary. Studied in people, but no published study has had people take it. 1 human study where nobody was given it.5 reported

    number of people not given0 studies
16. 16DHEAHormoneModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 267 people given it.5 reported

    number of people not given0 studies
17. 17BromantaneSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 728 people given it.6 reported

    number of people not given0 studies
18. 18ClenbuterolSmall moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 11 people given it.5 reported

    number of people not given0 studies
19. 19PQQSupplementModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 116 people given it.5 reported

    number of people not given0 studies
20. 20Modified GRF 1-29PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, none stating how many people.9 reported

    number of people not given0 studies
21. 21Vitamin DSupplementStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 25,871 people given it.4 reported

    number of people not given0 studies
22. 22MagnesiumSupplementLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 46 people given it.4 reported

    number of people not given0 studies

1. 01ErythropoietinBiologicStrong. At least two finished studies in people, and at least 1,000 people who took it. 3 completed trials, 4,641 people given it.6 reported

   4,038 people1 study

   • This drug did not extend life or save kidneys, and it doubled the risk of stroke. 4,038 people with type 2 diabetes, kidney disease and anaemia got darbepoetin alfa or a dummy shot, with rescue treatment if counts dropped too low. Death and heart events came out the same. Kidney failure came out the same. Strokes hit...

     New England Journal of Medicine, 2009 · 4,038 people

2. 02BromantaneSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 728 people given it.6 reported

   728 people1 study

   • The largest study of bromantane had nothing to compare itself against. 728 patients at 28 Russian clinics took it for four weeks. Nine in ten were rated improved by their doctor. Side effects were rare and almost nobody quit. Here is the problem. Everybody got the drug, everybody knew it, and the score was a doctor's...

     Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 2010 · 728 people

3. 03ElamipretidePeptideModerate. At least one finished study in people, and at least 100 people who took it. 5 completed trials, 487 people given it.6 reported

   218 people1 study1 found nothing

   • found nothingIt was tested properly, at full scale, and it failed. 218 people with an inherited muscle disease caused by faulty mitochondria got elamipretide or a dummy injection, and nobody involved knew which. Both of the things the trial was built to settle came out flat. Walking distance in six minutes was 3.2 metres worse on...

     Neurology, 2023 · 218 people

4. 04OxaloacetateSupplementModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 112 people given it.4 reported

   82 people1 study

   • Oxaloacetate cut fatigue more than the comparison group in people with ME and chronic fatigue syndrome. 82 people took 2,000 mg a day for three months, assigned by chance, and nobody involved knew who got what. Fatigue fell by more than a quarter in the treated group against roughly a tenth in the controls. About 40.5...

     Frontiers in Neurology, 2024 · 82 people

5. 05MifepristoneSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 320 people given it.4 reported

   50 people1 study

   • In Cushing's syndrome, where cortisol is the problem, blocking its receptor with mifepristone improved blood sugar, blood pressure and weight over six months. 50 adults took part, and there was no dummy pill group. Tiredness, nausea, headache and low potassium were common. This is the approved use, not a study of...

     The Journal of Clinical Endocrinology and Metabolism, 2012 · 50 people

6. 06MelittinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 5 completed trials, 658 people given it.4 reported

   26 people1 study

   • Bee sting therapy failed on every measure it was tested on. Twenty six people with relapsing multiple sclerosis were stung up to twenty times a session, three times a week, for six months. Brain scans showed no fewer new lesions. Relapses, disability, fatigue and quality of life were all unchanged. Nobody was...

     Neurology, 2005 · 26 people

7. 07Melanotan IIPeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 5 completed trials, 1,310 people given it.9 reported

   3 people1 study

   • The first look at this compound in people was tiny, and the side effect it turned up became the reason people buy it. Three male volunteers took shots under the skin for two weeks. Their skin darkened, which was the point. Most doses made them feel sick, and the highest left them drowsy and tired. They also got...

     Life Sciences, 1996 · 3 people

8. 08TestosteroneHormoneModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 5,246 people given it.10 reported

   number of people not given1 study1 found nothing

   • found nothingTestosterone helped older men with sex and did much less for everything else. It raised their levels to what a man in his twenties or thirties would have. Sex drive, sexual activity and erections all clearly got better. Energy did not get better at all. Walking distance only improved when three studies were lumped...

     New England Journal of Medicine, 2016 · number of people not given

9. 09RetatrutidePeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 5 completed trials, 1,345 people given it.8 reported

   number of people not given0 studies
10. 10Thymosin Beta-4PeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 5 completed trials, 1,382 people given it.9 reported

    number of people not given0 studies
11. 11Vitamin B12SupplementLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, none stating how many people.4 reported

    number of people not given0 studies
12. 12Urolithin ASupplementLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, none stating how many people.4 reported

    number of people not given0 studies
13. 13DasatinibSmall moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, 74 people given it.3 reported

    number of people not given0 studies
14. 14EnobosarmSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 159 people given it.5 reported

    number of people not given0 studies
15. 15CardarineSmall moleculePreliminary. Studied in people, but no published study has had people take it. 1 registered with no result.7 reported

    number of people not given0 studies
16. 16NattokinaseBiologicStrong. At least two finished studies in people, and at least 1,000 people who took it. 9 completed trials, 1,795 people given it.6 reported

    number of people not given0 studies
17. 17DHEAHormoneModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 267 people given it.5 reported

    number of people not given0 studies
18. 18LamivudineSmall moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, none stating how many people.3 reported

    number of people not given0 studies
19. 19PQQSupplementModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 116 people given it.5 reported

    number of people not given0 studies
20. 20NAD+ / B ComplexBlendLimited. People have taken it in a published study, but fewer than 100 of them. 5 completed trials, 34 people given it.8 reported

    number of people not given0 studies
21. 21Semaglutide with B12BlendLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, none stating how many people.7 reported

    number of people not given0 studies
22. 22Thymosin alpha-1 with KPV and LL-37BlendStrong. At least two finished studies in people, and at least 1,000 people who took it. 3 completed trials, 1,140 people given it.6 reported

    number of people not given0 studies
23. 23CoQ10SupplementModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 162 people given it.4 reported

    number of people not given0 studies
24. 24RusfertidePeptideModerate. At least one finished study in people, and at least 100 people who took it. 5 completed trials, 166 people given it.

    number of people not given0 studies